MedTrace Logo

Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction

NCT07168837 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-09-11

No results posted yet for this study

Summary

Polycystic Ovarian Syndrome (PCOS) is the most common endocrine disorders in women of reproductive age. According to the World Health Organization (WHO) estimation revealed over 116 million women (3.4%) are affected by PCOS worldwide.

Owing to the intricacy of this condition, various sets of diagnostic criteria have been initiated for the confirmation of PCOS which are: National Institute of Health, Rotterdam's Criteria, Androgen Excess and PCOS society. The prevalence of PCOS is estimated at about 4 to 21 % when it is diagnosed according to the Rotterdam criteria accounting for 75% of cases with anovulatory infertility.

Conditions

  • PCOS (Polycystic Ovary Syndrome)

Interventions

DRUG

Letrozole tablets

to compare between Letrozole withncabergoline and letrozole alone in ovulation induction among PCOS female patients.

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • El-Kotb Hasan El-Kotb El-Saeidy, Professor · Obstetrics and Gynecology Department, Faculty of medicine,Al-Azhar University, Assiut.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-10
Primary Completion
2024-05-01
Completion
2024-05-10

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07168837 on ClinicalTrials.gov